There are more than 19 billion overweight adults and 650 million obese ones globally, according to the World Health Organization ( Maintaining long-term weight control is challenging due to the metabolism variation ( Several anti-obesity drugs, such as orlistat, naltrexone-bupropion, phentermine-topiramate and liraglutide, have provided sufficient evidence on weight loss for adults ( Semaglutide, a novel, long-acting GLP-1 RAs, shows significant performance on weight reduction in several clinical trials ( Here, in this study, we conducted a comprehensive systematic review and meta-analysis to provide an up-to-date evaluation of semaglutide on efficacy and safety of weight loss, especially under the different administration situations, such as the weekly dosages, administration frequencies, trial durations, baseline obesity classifications and whether accompanied with lifestyle interventions
Transparent pricing, no hidden fees
Eur J Endocrinol, 153:963-969
Minkler PE, Brass EP, Hiatt WR, Ingalls ST, Hoppel CL